Company Overview
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.30.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -19.00% |
| 6 Months: | -38.70% |
| 3 Months: | -20.80% |
| 1 Month: | -37.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross3d ago
- RSI (14)24.66 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 51.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NKTX Nkarta, Inc. R2KR3KPHARMA | 1.79 | -1.13 | $128.21M | 0.00% | -31.94% | -38.76% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.31K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -4.67M | -5.91M | -9.41M | -10.36M | -13.75M | -19.48M | -21.63M | -22.43M | -26.10M | -27.61M | -30.26M | -34.31M | -36.86M | -29.29M | -32.76M | -30.71M | -33.79M | -36.56M | -27.19M | -27.29M | -30.88M |
| Net Income | -3.08M | -4.84M | -2.67M | -8.71M | -51.06M | -13.69M | -19.37M | -21.54M | -22.35M | -25.99M | -26.92M | -28.34M | -30.82M | -33.29M | -25.64M | -29.52M | -24.99M | -28.34M | -31.98M | -22.98M | -21.71M | -27.83M |
| Diluted EPS | - | - | - | - | - | - | - | -0.66 | -0.68 | -0.79 | -0.61 | -0.58 | -0.63 | -0.68 | -0.52 | -0.58 | -0.34 | -0.39 | -0.43 | -0.31 | -0.29 | -0.37 |
| R&D Expense | - | 3.62M | 4.62M | 7.26M | 7.86M | 9.83M | 13.54M | 15.96M | 16.62M | 19.57M | 21.05M | 23.43M | 26.14M | 25.12M | 22.19M | 25.24M | 23.13M | 25.25M | 24.17M | 20.78M | 20.20M | 24.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 115.00K | - | - | - | - | 0 | 0 |
| Operating Income | -22.35M | -51.51M | -86.43M | -118.95M | -131.65M | -128.19M | -122.00M |
| Net Income | -21.08M | -91.36M | -86.08M | -113.84M | -117.50M | -108.79M | -104.08M |
| Diluted EPS | - | - | -2.62 | -2.61 | -2.40 | -1.60 | -1.41 |
| R&D Expense | 17.22M | 36.22M | 63.41M | 90.90M | 96.77M | 96.74M | 90.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 48.41M | 337.65M | 273.90M | 472.94M | 378.88M | 501.20M | 404.21M |
| Total Equity | -5.40M | -25.48M | 321.22M | 250.97M | 372.21M | 273.29M | 407.98M | 312.32M |
| Cash & Equivalents | - | 20.61M | 96.69M | 60.82M | 37.49M | 31.04M | 27.87M | 39.63M |
| Total Liabilities | - | 14.08M | 16.43M | 22.94M | 100.73M | 105.60M | 93.23M | 91.88M |
| Current Liabilities | - | 8.16M | 8.83M | 12.94M | 22.05M | 23.33M | 18.92M | 22.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.37M | -43.51M | -67.93M | -57.00M | -86.16M | -99.70M | -88.70M |
| Investing Cash Flow | -18.30M | -210.08M | 32.53M | -184.69M | 79.02M | -129.56M | 100.32M |
| Financing Cash Flow | 49.58M | 329.82M | 1.20M | 219.01M | 691.00K | 226.08M | 141.00K |
| Capital Expenditure | -1.93M | -7.51M | -5.03M | -47.11M | -28.15M | -4.41M | -1.21M |
| Free Cash Flow | -20.30M | -51.02M | -72.95M | -104.11M | -114.31M | -104.11M | -89.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -19,433.9% | - | - | - | - | - | - |
| Net Margin % | -18,327.0% | - | - | - | - | - | - |
| ROE % | 82.7% | -28.4% | -34.3% | -30.6% | -43.0% | -26.7% | -33.3% |
| ROCE % | -55.5% | -15.7% | -33.1% | -26.4% | -37.0% | -26.6% | -31.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 15.09% | 10.81M | $24.31M |
| 2 | Blackrock Inc. | 8.80% | 6.30M | $14.18M |
| 3 | NEA Management Company, LLC | 4.98% | 3.57M | $8.03M |
| 4 | Samsara BioCapital, LLC | 4.90% | 3.51M | $7.89M |
| 5 | SR One Capital Management, LP | 4.65% | 3.33M | $7.50M |
| 6 | GSK plc | 4.40% | 3.15M | $7.09M |
| 7 | Monaco Asset Management SAM | 3.31% | 2.37M | $5.34M |
| 8 | Vanguard Capital Management LLC | 3.11% | 2.23M | $5.01M |
| 9 | Citadel Advisors Llc | 3.04% | 2.17M | $4.89M |
| 10 | Two Sigma Investments, LP | 2.62% | 1.87M | $4.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NKTX
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNZ0dqcWpsdlVxWnFySzUyTVZJODlsYWxYUnJKZ3FDMmt3UlZOc0U2SkQyX3dJYTNMTThqUEdiNzFxeGJRVEpnb0U1OHRiQ0Z5TXAyRm9SU2ZoazR1UTFRZUV3Y3JGd1VKckNRS2FXYTYxb3QyalVFQ0VDU2M3YzBWWTNNd1o3SHNFNkZXUX…
Should I buy Nkarta (NKTX) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9lQkQwZkt2NDNmWk1Ic2VVOFEzdFctbFdEWlhFQUR5aURyN28zdk11SW5McGs1ZDYzUG1Xa1Y0cHhNTXJIUUhZWkxpUVFvdmYzUnU0Y05UaHdDWEtmNkxDT2R0SUEweXlLZ0d4UA?oc=5" target="_blank">Should I buy Nkarta (…
NKTX May 2027 2.500 call (NKTX270521C00002500) stock historical prices and data - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1wV2FHUlpkUHVQWHdoSWU2UEIyU2xIQmJKTjR6ZHdlb2s4amU3bDNkM2FBMTN2ekdzRHI4cHFpT1dpTndJdDA3Xzl4TUFTYVlqWERNVV9VZWQ1cDlIUzh0cFk3cEVpNi15eEU1dUltX00?oc=5" target="_blank">NKTX May 2027 2.…
TD Cowen initiates Nkarta stock with buy rating on NK cell therapy - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPRm1yQW1pOHlsYU91SllZZlVJUVRuTkxTY0VkMzVrRmg1eTNmU21hOExuOWUyWXJiN2RrV3RPdzJaQWR3dnFCa084RU1VRlhUUWhwZVRMVVJWaUxQcjdZaGF6b0xEMTFqS1BxRmh2YmswZmdESjIxQ1NMeWpnSFZvRVVmM05zQkVPR0c3UF…
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQTjRYQTh1OGVEMDlLaHFIZ1dOZ3FhZ2I5dXdkbVRlS0JaeUtrOHh4NzM3YU5EYy12NDVoRnFpYWxCb3ItNVR6YjBoR3gxbDNDTXRNQzh1WGlqZ1dNMkNPaFhLZVI1c0N3ZlpjVjJpMld2c0k2RlJMZlFfY2FWM2hZT2JRWGpobFR0LWpHUl…
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNLW16aENrQkt1LW5LcEhFZXY0cThBSDF6cWpSOFEwOG1OQmluZDF4end4bjg5ZUhZV0FxZVY5YVFjdEZtdWtzS0lnZlZxd2JIbDl0MTRvTXFFclI0SVB0X0hhcmhMbFdDc1E3S1FPY1hYWjF5VmlFX19xMEczdmY3NHp6bkFNVVh1VnJZWl…
NKTX — Frequently Asked Questions
What is the current share price of Nkarta, Inc. (NKTX)?
As of 2026-10-23 16:27 PDT, Nkarta, Inc. (NKTX) trades at $1.79 on NasdaqGS. Its 52-week range is $1.73 to $3.67.
What is the market capitalisation of NKTX?
Nkarta, Inc. (NKTX) has a market capitalisation of $128.21M on NasdaqGS.
What is the P/E ratio of NKTX?
NKTX trades at a trailing price-to-earnings (P/E) ratio of -1.13. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.82.
What is the return on equity (ROE) of NKTX?
NKTX has a return on equity (ROE) of -38.76%. Its return on capital employed (ROCE) is -31.94%.
Is NKTX a good stock to buy?
This page provides a data-driven analysis of Nkarta, Inc. (NKTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.